Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Update March 2022

Wolf, S. (2021): Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC). Update March 2022. Oncology Fact Sheet Nr. 61.

[thumbnail of Oncology Fact Sheet Nr.61_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
707kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WF Respiratory system
Language:	English
Series Name:	Oncology Fact Sheet Nr. 61
Deposited on:	15 Oct 2021 15:13
Last Modified:	03 Mar 2022 00:04

Repository Staff Only: item control page